RA
FLXN

Royce & Associates’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Royce & Associates’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-451,037
Closed -$3.71M – 1039
2021
Q2 		$3.71M Sell
451,037
-106,400
-19% -$905K 0.03% 661
2021
Q1 		$4.99M Sell
557,437
-70,057
-11% -$803K 0.03% 598
2020
Q4 		$7.24M Sell
627,494
-74,000
-11% -$860K 0.06% 465
2020
Q3 		$7.3M Buy
701,494
+34,000
+5% +$417K 0.08% 374
2020
Q2 		$8.78M Buy
667,494
+91,000
+16% +$944K 0.1% 300
2020
Q1 		$4.54M Buy
576,494
+235,192
+69% +$3.54M 0.06% 400
2019
Q4 		$7.07M Buy
341,302
+16,294
+5% +$275K 0.06% 408
2019
Q3 		$4.45M Buy
325,008
+218,384
+205% +$2.59M 0.04% 507
2019
Q2 		$1.31M Buy
106,624
+91,600
+610% +$1.06M 0.01% 804
2019
Q1 		$187K Buy
+15,024
New +$201K ﹤0.01% 997
2018
Q4 		– Sell
-44,795
Closed -$838K – 1222
2018
Q3 		$838K Hold
44,795
– – 0.01% 945
2018
Q2 		$1.16M Hold
44,795
– – 0.01% 916
2018
Q1 		$1M Hold
44,795
– – 0.01% 967
2017
Q4 		$1.12M Sell
44,795
-5,205
-10% -$127K 0.01% 956
2017
Q3 		$1.21M Hold
50,000
– – 0.01% 915
2017
Q2 		$1.01M Hold
50,000
– – 0.01% 974
2017
Q1 		$1.35M Buy
+50,000
New +$1.02M 0.01% 935

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's FLXN Position: Q3 2021 in Review

Royce & Associates sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 451,037 shares — an estimated $3.71M sold.

Royce & Associates first reported a position in FLXN in Q1 2017 and held it in 17 quarters. The position peaked at $8.78M in Q2 2020. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

  • Royce & Associates reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Royce & Associates sold 451,037 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $3.71M.
  • Royce & Associates first reported a position in Flexion Therapeutics, Inc. in Q1 2017 and held it in 17 quarters.
  • Royce & Associates's Flexion Therapeutics, Inc. position peaked at $8.78M in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Royce & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.